Since IFN-γ is involved in the development of EAMG in both acute and chronic MG stages, blocking IL-18 with anti-IL-18 antibodies or disrupting CD40-CD40L interaction was found to suppress MG severity (165). This evidence concerns the gene IL18 and myasthenia gravis.